The Editor-in-Chief has retracted this article [1] due to concerns regarding the figures and the underlying data. The authors informed the journal that they have not been able to reproduce the results presented in the article. Further investigation found significant text overlap with an article by different authors that was simultaneously under consideration at the same time at another journal [2]. Additionally, there appear to be overlapping figures between the two articles:
The bottom left two panels of Figure 4F of [1] appear to be identical to the bottom left and bottom right panels of Figure 2B of [2]
The TAC panel in Figure 4G of [1] TAC image appears to be a reflection (y axis) of the TAC+control in Figure 4G of [1].
The data reported in this article are therefore unreliable Changsheng Ma agrees to this retraction. The other authors have not responded to correspondence regarding this retraction.
The online version of this article contains the full text of the retracted article as electronic supplementary material.
Change history
02 August 2020
A Correction to this paper has been published: https://doi.org/10.1038/s41434-020-0180-6
References
Wang, W., Liu, N., Xin, L. et al. Inhibition of miR-296-5p protects the heart from cardiac hypertrophy by targeting CACNG6. Gene Ther (2019). https://doi.org/10.1038/s41434-019-0109-0.
Xu L, Wang H, Jiang F, Sun H, Zhang D. LncRNA AK045171 protects the heart from cardiac hypertrophy by regulating the SP1/MG53 signalling pathway. Aging (Albany NY). 2020; 12:3126–3139. https://doi.org/10.18632/aging.102668.
Author information
Authors and Affiliations
Corresponding author
Additional information
The Editor-in-Chief has retracted this article due to concerns regarding the figures and the underlying data. The authors informed the journal that they have not been able to reproduce the results presented in the article.
Electronic supplementary material
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Wang, W., Liu, N., Xin, L. et al. RETRACTED ARTICLE: Inhibition of miR-296-5p protects the heart from cardiac hypertrophy by targeting CACNG6. Gene Ther 28, 391 (2021). https://doi.org/10.1038/s41434-019-0109-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41434-019-0109-0
This article is cited by
-
RETRACTED ARTICLE: Inhibition of miR-296-5p protects the heart from cardiac hypertrophy by targeting CACNG6
Gene Therapy (2021)
-
Empagliflozin prevents doxorubicin-induced myocardial dysfunction
Cardiovascular Diabetology (2020)
-
Gene therapy for cardiovascular diseases in China: basic research
Gene Therapy (2020)
-
Retraction Note: Inhibition of miR-296-5p protects the heart from cardiac hypertrophy by targeting CACNG6
Gene Therapy (2020)
